
A phase 2 study evaluates linvoseltamab's safety and efficacy in high-risk smoldering myeloma, focusing on response rates and MRD negativity.

A phase 2 study evaluates linvoseltamab's safety and efficacy in high-risk smoldering myeloma, focusing on response rates and MRD negativity.

Experts explore the evolving treatment strategies for high-risk smoldering multiple myeloma, highlighting studies that show early intervention can improve patient outcomes.

Research explores innovative treatments for high-risk smoldering multiple myeloma, highlighting promising results from the bispecific antibody linvoseltamab.

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.

HBI0101, an academically sourced CAR T-cell therapy, demonstrated a high objective response rate and manageable safety in patients with relapsed/refractory multiple myeloma.

The 2024 International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in multiple myeloma research and treatment.

Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.

A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.


A real-world analysis of cilta-cel in patients with relapsed/refractory multiple myeloma showed deep and durable responses, with a safety profile consistent with clinical trial data.

A new study found that adding daratumumab to lenalidomide, bortezomib, and dexamethasone significantly improved outcomes for older patients with newly diagnosed multiple myeloma.

A new combination therapy involving sonrotoclax and dexamethasone demonstrated safety, antitumor activity, and early responses in heavily pretreated patients with relapsed/refractory multiple myeloma harboring t(11:14).

A novel, all-oral combination regimen of mezigdomide, tazemetostat, and dexamethasone demonstrated early signals of activity and a tolerable safety profile in patients with highly refractory multiple myeloma.

A new combination therapy involving belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone showed promising results in patients with multiple myeloma who had received 1 prior line of therapy.

A new allogeneic CAR T-cell therapy, P-BCMA-ALLO1, has shown promising results in treating heavily pretreated patients with relapsed/refractory multiple myeloma.

The CARTITUDE-4 study found that cilta-cel reduced the risk of death by 45% compared to standard of care in patients with multiple myeloma.

Ashraf Z. Badros, MB, ChB, discusses the key takeaways from the phase 3 AURIGA trial.

A study found that anito-cel is a promising CAR T-cell therapy for relapsed/refractory multiple myeloma with high efficacy and manageable safety.

A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma with high response rates and manageable adverse effects.

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, offering a promising approach to deeper disease response.

Maintenance therapy with daratumumab and lenalidomide led to higher MRD-negative conversion rates compared to lenalidomide alone in newly diagnosed multiple myeloma patients following transplant.

Isa-KRd showed deep responses, high MRD negativity rates, and manageable safety in patients with newly diagnosed, transplant-eligible multiple myeloma, as per interim analysis of the IFM2020-02 MIDAS study.

In TRIMM-2, an overall response rate of 82% was seen amon patients given talquetamab plus daratumumab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS, discusses some of the challenges often seen in the myeloma space, particularly those with lenalidomide-refractory multiple myeloma.

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated multiple myeloma, with high response rates and durable responses.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Positive response and preliminary evidence of longer progression-free survival was observed with a venetoclax-based triplet therapy vs a doublet, in a phase. 2 study.

The observed benefits of ciltacabtagene autoleucel in patients with multiple myeloma and poor prognostic features are consistent with the overall the population of CARTITUDE-4.

NXC-201 has demonstrated safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel was shown to be effective when used in patients with multiple myeloma exhibiting poor prognostic features.